Cargando…
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug resistance, limiting overall benefit. Here we rep...
Autores principales: | Guijarro, Maria V., Kellish, Patrick C., Dib, Peter E., Paciaroni, Nicholas G., Nawab, Akbar, Andring, Jacob, Kulemina, Lidia, Borrero, Nicholas V., Modenutti, Carlos, Feely, Michael, Nasri, Elham, Seifert, Robert P., Luo, Xiaoping, Bennett, Richard L., Shabashvili, Daniil, Licht, Jonathan D., McKenna, Robert, Roitberg, Adrian, Huigens, Robert W., Kaye, Frederic J., Zajac-Kaye, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386886/ https://www.ncbi.nlm.nih.gov/pubmed/37097751 http://dx.doi.org/10.1172/jci.insight.158798 |
Ejemplares similares
-
TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background
por: Guijarro, Maria V., et al.
Publicado: (2023) -
MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription
por: Liu, Tingting, et al.
Publicado: (2019) -
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors
por: Wróbel, Agnieszka, et al.
Publicado: (2019) -
Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival
por: Vijayakurup, Vinod, et al.
Publicado: (2022) -
Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan
por: Awab, Ghulam R, et al.
Publicado: (2013)